Harnessing The Immune Response: Developing a Novel Multi-Modal Virotherapy For Pancreatic Adenocarcinoma
Year: 2023
Type: article
Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal form of cancer with little improvement in treatment in recent years. The late presentation of aggressive disease in an often frail population makes PDAC an ideal candidate for highly targeted therapies which might be administered systemically and offer little off-target side-effects. Oncolytic virus therapy (OVT) offers this potential but as yet, no platform has been developed to deliver its promise. Building on the VVL-STC platform developed by the Professor Wang group, four novel Lister-strain vaccinia virus platforms were constructed. These viruses were engineered to target MAGE-A tumour associated antigens, identified as expressed in PDAC and able to elicit immune responses as well as produce immune-modulating agents, soluble PD-1 and soluble CD154 either individually or in concert. Each virus was constructed using CRISPR/Cas9 guided recombination of transgenes, designed specifically for this purpose, to the N1L locus of VVL-STC before undergoing purification and validation of replication competence and cytotoxicity assessment. Production of transgene products was assessed and viruses then tested in vivo to ascertain antitumour effect in an immunocompetent mouse model. Improved survival and complete tumour response was seen in a number of mice, with significant but non-sustained response in others. Combination therapy proved unsuccessful and requires further investigation into the reason for this. This study shows the potential for augmented vaccinia virus therapy using a number of approaches to augmentation and justifies further investigation to determine treatment schedules and dosing, including full assessment of the tumour microenvironment response to OVT, before further trials in orthotopic and spontaneous tumour mouse models. With appropriate further studies, vaccinia virus OVT may soon reach phase 1 clinical trials and begin to make an impact on treatment of PDAC.
Author: STEVENS, L
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7028655544
